BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10834852)

  • 1. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?
    Braun J; Sieper J
    Ann Rheum Dis; 2000 Jun; 59(6):404-7. PubMed ID: 10834852
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
    Braun J; de Keyser F; Brandt J; Mielants H; Sieper J; Veys E
    Curr Opin Rheumatol; 2001 Jul; 13(4):245-9. PubMed ID: 11555723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
    St Clair EW
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
    Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
    Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies. two case reports.
    Kaiser MJ; Sany J
    Joint Bone Spine; 2001 Dec; 68(6):525-7. PubMed ID: 11808993
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis onset during infliximab treatment: description of two cases.
    Volpe A; Caramaschi P; Carletto A; Pieropan S; Bambara LM; Biasi D
    Rheumatol Int; 2006 Oct; 26(12):1158-60. PubMed ID: 16738903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumour necrosis factor-alpha in patients with chronic hepatitis C infection.
    Zavos C; Kountouras J; Zavos N; Chatzopoulos D
    Clin Rheumatol; 2007 Feb; 26(2):283. PubMed ID: 17003955
    [No Abstract]   [Full Text] [Related]  

  • 12. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ankylosing spondylitis with infliximab.
    Boeger CA; Wittwer H; Schattenkirchner M; Kellner H; Kellner W
    Ann Rheum Dis; 2001 Dec; 60(12):1159-60. PubMed ID: 11760727
    [No Abstract]   [Full Text] [Related]  

  • 15. [New results from studies of therapy of ankylosing spondylitis with infliximab].
    Braun J
    Z Rheumatol; 2003 Apr; 62(2):108-9. PubMed ID: 12820612
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court].
    Sieper J
    Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies in the treatment of spondyloarthritis.
    Maksymowych WP
    Expert Opin Investig Drugs; 2002 Jul; 11(7):937-46. PubMed ID: 12084004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.